Quick Answer
QIAGEN N.V. reported Revenue (ASC 606) of $2.09 billion for fiscal year 2025.
QIAGEN N.V. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $2.09B | +5.7% |
| 2024 | $1.98B | +0.7% |
| 2023 | $1.97B | -8.2% |
| 2022 | $2.14B | -4.9% |
| 2021 | $2.25B | +20.4% |
| 2020 | $1.87B | +22.5% |
| 2019 | $1.53B | +1.6% |
| 2018 | $1.50B | +5.9% |
| 2017 | $1.42B | +5.9% |
| 2016 | $1.34B | — |
- QIAGEN N.V. showed an increase of +5.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, QIAGEN N.V.’s revenue (asc 606) has grown by 56.2% (from $1.34 billion to $2.09 billion).
- The most recent figure is from QIAGEN N.V.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: